On August 11, 2026, Vancouver-based biotech AbCellera Biologics reported positive Phase 2 results for ABCL635, a long-acting, non-hormonal antibody treatment for menopausal hot flashes — and the market noticed, sending the stock surging as much as 41%. The trial met its primary efficacy endpoints, cutting both the frequency and severity of vasomotor symptoms in postmenopausal women.

Why It Matters

Menopause tech and treatment is one of the fastest-maturing corners of femtech, and the pipeline has been dominated by NK3-pathway small molecules and hormone therapy. An antibody with a dosing cadence measured in weeks rather than days would be a genuinely differentiated product — reducing adherence friction and appealing to the large cohort of women who avoid or can't take HRT. For investors, the 41% pop underscores how much upside the market now assigns to credible non-hormonal menopause assets, a category that also includes recent NHS wins for fezolinetant and a wave of menopause-focused telehealth and wearables. It also raises competitive pressure on Astellas and Bayer, both of whom have staked positions in the vasomotor-symptom market.

In the study of 92 postmenopausal women who each reported roughly 10 moderate-to-severe hot flashes per day, participants who received a single 600 mg subcutaneous dose of ABCL635 had 83% fewer hot flashes after four weeks, versus 33% in the placebo group. The drug targets the neurokinin-3 receptor (NK3R) — the same thermoregulatory pathway addressed by small-molecule drugs like Astellas' fezolinetant (Veoza) — but as a long-acting injectable antibody rather than a daily pill. AbCellera reported the treatment was well-tolerated and also improved sleep quality and patients' overall assessment of improvement.

"These positive results represent a significant milestone for women's health and for AbCellera," said Sarah Noonberg, M.D., Ph.D., the company's Chief Medical Officer, framing ABCL635 as a potentially well-tolerated, long-acting option that could "markedly improve" quality of life for menopausal women. Roughly 75% of women in menopause experience hot flashes, yet treatment has largely been limited to hormone replacement therapy — used by fewer than half of women — and lifestyle changes. Roughly 2 million women enter menopause in the U.S. each year.

Analysts read the data as strategically pointed: FierceBiotech noted the women's-health results topped the "most aggressive upside scenario," putting incumbents Astellas and Bayer "on notice." AbCellera's trials are ongoing to further establish safety and efficacy in vasomotor symptoms, positioning the company for a possible pivotal program.

Sources

Update — 2026-08-16

Initial entry — story first created.